Expression data of iPSC-derived motor neurons from healthy donor, FALS, SALS, and drug-treated them

We established several iPSCs from healthy donors, familial ALS (FALS) patients, and sporadic ALS (SALS) patients. Using our differentiation protocol originally developed, we differentiated these iPSCs toward spinal motor neurons (MNs) and reproduced ALS pathology in a dish. In addition, we screened a drug candidate which suppressed the detected ALS-related phenotypes of these ALS models. For clarifying the molecular mechanisms of the ALS pathologies and the screened drug, we used microarrays to detail the global program of gene expression reflecting the MN pathology of FALS/SALS, and carefully compared with healthy donors and/or drug-treated ALS models based on their expression profiles. We isolated RNA from iPSC-derived MNs (healthy donor: 4 samples, untreated FALS: 6 samples, untreated SALS: 4 samples, drug-treated FALS: 6 samples, drug-treated SALS: 4 samples. Total 24 samples) for the gene expression microarray analysis. All of the iPSC lines we used were low passage number (less than 15).